Abstract
The Ang II type 1 receptor (AT1R)-associated protein (ATRAP/Agtrap) is a molecule specifically interacting with the carboxyl- terminal domain of AT1R. The results of in vitro studies showed that ATRAP suppresses Ang II-mediated pathological responses in cardiovascular cells by promoting AT1R internalization. With respect to the tissue distribution and regulation of ATRAP expression in vivo, ATRAP is broadly expressed in many tissues as is AT1R. Accumulating evidence indicates that a tissue-specific regulatory balancing of ATRAP and AT1R expression may be involved in the modulation of AT1R signaling at local tissue sites and also in the pathophysiology of hypertension and its associated end-organ injury. Furthermore, the activation of ATRAP in transgenic-models inhibited inflammatory vascular remodeling and cardiac hypertrophy in response to Ang II stimulation. These results suggest the clinical potential benefit of an ATRAP activation strategy in the treatment of hypertension and related organ injury.
Keywords: Gene expression/regulation, hypertension, receptor internalization, receptor signaling, renin-angiotensin system, target organ injury.
Current Pharmaceutical Design
Title:The Physiology and Pathophysiology of a Novel Angiotensin Receptor-binding Protein ATRAP/Agtrap
Volume: 19 Issue: 17
Author(s): Shin-ichiro Masuda, Satoshi Umemura, Akio Yamashita, Yasuo Tokita, Yoshiyuki Toya, Miyuki Matsuda, Yuko Tsurumi-Ikeya, Yuichi Koide, Atsu-ichiro Shigenaga, Koichi Azuma, Kouichi Tamura, Kazushi Uneda, Sona Haku, Tomohiko Kanaoka, Kengo Azushima, Masato Ohsawa, Toru Dejima, Akinobu Maeda and Hiromichi Wakui
Affiliation:
Keywords: Gene expression/regulation, hypertension, receptor internalization, receptor signaling, renin-angiotensin system, target organ injury.
Abstract: The Ang II type 1 receptor (AT1R)-associated protein (ATRAP/Agtrap) is a molecule specifically interacting with the carboxyl- terminal domain of AT1R. The results of in vitro studies showed that ATRAP suppresses Ang II-mediated pathological responses in cardiovascular cells by promoting AT1R internalization. With respect to the tissue distribution and regulation of ATRAP expression in vivo, ATRAP is broadly expressed in many tissues as is AT1R. Accumulating evidence indicates that a tissue-specific regulatory balancing of ATRAP and AT1R expression may be involved in the modulation of AT1R signaling at local tissue sites and also in the pathophysiology of hypertension and its associated end-organ injury. Furthermore, the activation of ATRAP in transgenic-models inhibited inflammatory vascular remodeling and cardiac hypertrophy in response to Ang II stimulation. These results suggest the clinical potential benefit of an ATRAP activation strategy in the treatment of hypertension and related organ injury.
Export Options
About this article
Cite this article as:
Masuda Shin-ichiro, Umemura Satoshi, Yamashita Akio, Tokita Yasuo, Toya Yoshiyuki, Matsuda Miyuki, Tsurumi-Ikeya Yuko, Koide Yuichi, Shigenaga Atsu-ichiro, Azuma Koichi, Tamura Kouichi, Uneda Kazushi, Haku Sona, Kanaoka Tomohiko, Azushima Kengo, Ohsawa Masato, Dejima Toru, Maeda Akinobu and Wakui Hiromichi, The Physiology and Pathophysiology of a Novel Angiotensin Receptor-binding Protein ATRAP/Agtrap, Current Pharmaceutical Design 2013; 19 (17) . https://dx.doi.org/10.2174/1381612811319170010
DOI https://dx.doi.org/10.2174/1381612811319170010 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Beta-blockers in the Perioperative Period: Are there Indications other than Prevention of Cardiac Ischemia?
Current Drug Targets Methyl 2-Methoxycarbonyl-3-Phenylpropionate Derivatives: A New Type of Angiotensin Converting Enzyme Inhibitors
Letters in Organic Chemistry Role of Hyperglycaemia in Pathogenesis of Diabetic Cardiovascular Disease
Vascular Disease Prevention (Discontinued) The Coronary Collateral Circulation in Man
Current Cardiology Reviews Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets Bioactive Small Molecules: Promising Novel Therapies in Cardiovascular Diseases – PART I
Current Topics in Medicinal Chemistry Gender Differences in Characteristics and Outcome in Primary Intraventricular Hemorrhage
Current Neurovascular Research Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential
Current Neuropharmacology The Role of Transforming Growth Factor-β1 Gene Polymorphism and Its Serum Levels in Hashimoto’s Thyroiditis
Current Pharmaceutical Biotechnology Relaxin, Insulin and Diabetes: An Intriguing Connection
Current Diabetes Reviews Screening of Enzyme Inhibitors from Traditional Chinese Medicine
Combinatorial Chemistry & High Throughput Screening Advancement in Obesity Management: Leptin and Adiponectin Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Erectile Dysfunction and Coronary Artery Disease in Patients with Diabetes
Current Diabetes Reviews New Pathways for Reactive Oxygen Species Generation in Inflammation and Potential Novel Pharmacological Targets
Current Pharmaceutical Design Antioxidant Activity of Two Wild Edible Mushrooms (Morchella vulgaris and Morchella esculanta) from North Turkey
Combinatorial Chemistry & High Throughput Screening C-Reactive Protein: Interaction with the Vascular Endothelium and Possible Role in Human Atherosclerosis
Current Pharmaceutical Design Herb-Drug Interactions: An Evidence Based Approach
Current Medicinal Chemistry Bioactive Peptides in Preventative Healthcare: An Overview of Bioactivities and Suggested Methods to Assess Potential Applications
Current Pharmaceutical Design Cardiovascular Complications in Inflammatory Bowel Disease
Current Drug Targets Blockade of the Renin-Angiotensin-Aldosterone System: Effects on Hypertensive Target Organ Damage
Cardiovascular & Hematological Agents in Medicinal Chemistry